Enhanced Dissolution Rate of Glipizide by a Liquisolid Technique

DOI:

https://doi.org/10.37285/ijpsn.2010.3.4.5

Authors

  • Hitendra S Mahajan
  • Manoj R Dhamne
  • Surendra G. Gattani,
  • Ashwini D Rasal
  • Hannan T Shaikh

Abstract

This study aims to prepare immediate release glipizide liquisolid tablets using Avicel PH-102 and Aerosil 200 as the carrier and coating material respectively to increase dissolution rate of poorly soluble glipizide. This study also aims to evaluate treated Gellan gum as disintegrant in the preparation of liquisolid tablets. The solubility of glipizide was increased by use of liquisolid technique. The glipizide liquisolid tablets were evaluated for characteristics like drug content, friability, hardness, disintegration time, thermal analysis, X-ray diffraction (XRD) study and dissolution rates. The dissolution patterns of glipizide liquisolid tablets, carried out according to USP paddle method, and were compared with their commercial counterparts. The results obtained shows that all glipizide liquisolid tablets exhibits higher dissolution rates than those of marketed glipizide tablets. Dissolution rates increases with increasing concentration of liquid vehicles and maximum drug release achieved by formulations containing Polyethylene glycol 400 (PEG 400) as a liquid vehicle. The results of XRD and thermal analysis did not show any changes in crystallinity of drug and interaction between glipizide and excipients during the formulation process. 

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Glipizide, liquisolid tablets, dissolution rate enhancement, non-volatile solvents

Downloads

Published

2011-02-28

How to Cite

1.
Mahajan HS, Dhamne MR, Gattani, SG, Rasal AD, Shaikh HT. Enhanced Dissolution Rate of Glipizide by a Liquisolid Technique. Scopus Indexed [Internet]. 2011 Feb. 28 [cited 2024 Nov. 22];3(4):1205-13. Available from: https://ijpsnonline.com/index.php/ijpsn/article/view/538

Issue

Vol. 3 No. 4 (2010): January-March 2011

Section

Research Articles
Crossref
Scopus
Google Scholar
Europe PMC

References

Abdou H. Dissolution, Bioavailability and Bioequivalence, Edison Mack Publishing Co., Easton, PA, 1989, pp53–72.

Ammar HO, Salama HA, Ghorab M, El-Nahhas SA, and Elmotasem HA. Transdermal delivery system for glipizide. Current Drug Delivery. 3: 333-341(2006).

Fahmy RH, and Kassem MA. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: In vitro and in vivo evaluation. Eur. J. Pharm. Biopharm. 69: 993-1003(2008).

Foster RH, and Plosker GL. Glipizide: a review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus. Pharmacoeconomics. 18: 289-306(2000).

Indian Pharmacopoeia, Ministry of health and family welfare, Government of India, 1996.

Jamzad S, and Fassihi R. Development of controlled release low dose class II drug-glipizide. Int. J. Pharm. 312: 24–32.

Jamzad S, and Fassihi R. Role of surfactant and pH on dissolution properties of fenofibrate and glipizide: A technical note. AAPS PharmSciTech. 7 (2): Art. 33, E1-E6 (2006).

Javadzadeh Y, Siahi-Shadbad MR, Barzegar-Jalali M, and Nokhodchi A. Enhancement of dissolution rate of piroxicam using liquisolid compacts. Il Farmaco. 60: 361–365 (2005).

Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods. 44: 235-249 (2000).

Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting. Adv. Drug. Deliv. 23: 3-25 (1997).

Nokhodchi A. The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts. J. Pharm. Sci. 8 (1): 18–25 (2005).

Rao NR, Sudhakar G, and Srinath N. Current status of dispersible dosage Forms. Int. J. Pharm. Excip. 1 (1): 25 (2002).

Shiyani B, Gattani, SG, and Surana SJ. Formulation and evaluation of bi-layer tablet of metoclopramide hydrochloride and ibuprofen. AAPS PharmsciTech. 2008.

Spireas S, and Bolton M. Liquisolid Systems and Methods of Preparing Same. U. S. Patent 5, 968,550 (1999).

Spireas S, and Sadu S. Enhancement of prednisolone dissolution properties using liquisolid compacts. Int. J. Pharm. 166: 177–188(1998).

Spireas S. Liquisolid Systems and Methods of Preparing Same. US Patent 6,423,339 B1 (2002).

Spireas S, Sadu S, and Grover R. In-vitro release evaluation of hydrocortisone liquisolid tablets. J. Pharm Sci. 87 (7): 867–872 (1998).

Spireas SS, Jaroski CI, and Rohera BD. Powdered solution technology: Principles and Mechanism. Pharm. Res. 9(10): 1351-1358 (1992).

Spireas, SS, Wang T, and Grover R. Effect of powder substrate on the dissolution properties of methyclothiazide liquisolid compacts. Drug Devel. Ind. Pharm. 25(2): 163–168(1999).

USP/NF. Physical tests: Disintegration (701). 22/17 ed. Rockville, MD: United States Pharmacopoeial convention Inc, 1990.